Used in targeted cancer therapy, particularly for soft tissue sarcomas and melanomas expressing FZD10. Binds specifically to the Frizzled-10 receptor, blocking Wnt signaling pathway activation, which is often dysregulated in tumor cells. This inhibition suppresses tumor growth and promotes apoptosis. Investigated in clinical trials for its potential in immunotherapy, especially in combination with checkpoint inhibitors. Also serves as a reference standard in developing biosimilars and diagnostic assays targeting FZD10.